Change over period: —
NSE · ACUTAAS
ACUTAAS
-1.2% from the 52-week high · +149.1% above the low
Acutaas Chemicals Ltd produces specialty chemicals, intermediates, and industrial solutions. The company serves pharmaceutical, agricultural, and manufacturing sectors. Its operations include R&D, production, quality assurance, and logistics. By delivering consistent and innovative chemical solutions, it supports client operations and industrial growth.
The short version. ACUTAAS reported revenue of ₹437 crore for Sep 2026, up 42.8% from a year earlier. Net profit was ₹125 crore (up 73.6% year on year). Return on equity was 21.5% in Mar 2026. Promoter holding was 32.66% in Sep 2026, down 3.30 points over 8 quarters.
1 · The price
How has the stock traded?
ACUTAAS trades 1.2% below its 52-week high and 149.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹437 cr.
Sep 2026 net profit of ₹125 cr.
5.0 pts higher than a year earlier.
Revenue compounded at 30.5% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 437 | 330 | 433 | 393 | 306 | 207 | 308 | 275 |
| Net profit | 125 | 74 | 132 | 108 | 72 | 44 | 62 | 45 |
| Net margin % | 28.6 | 22.5 | 30.4 | 27.5 | 23.6 | 21.4 | 20.3 | 16.3 |
| EPS (₹) | 15.29 | 9.07 | 16.09 | 13.19 | 8.82 | 5.41 | 7.63 | 5.49 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | 1339 | 1007 | 717 | 617 | 520 |
| Net profit | 356 | 159 | 43 | 83 | 72 |
| Net margin % | 26.6 | 15.8 | 6.0 | 13.5 | 13.8 |
| EPS (₹) | 43.51 | 19.39 | 5.8 | 11.43 | 9.87 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 21.5% in Mar 2026; debt to equity is 0.02.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 21.5 | 12.1 | 6.3 | 14.0 |
| Return on capital % | 27.7 | 16.5 | 10.8 | 19.0 |
| EBITDA margin % | 37.8 | 24.3 | 14.3 | 20.4 |
| Net margin % | 25.8 | 15.5 | 5.9 | 13.4 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 30.5% | — |
| Profit CAGR | 62.3% | — |
4 · The owners
Who holds it, and are they adding?
Down 3.3 pts over 8 quarters.
Up 7.1 pts over 8 quarters.
Down 0.84 pts over 8 quarters.
+36 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 35.96 | 35.96 | 32.66 | 32.66 | 32.66 | 32.66 | 32.66 | 32.66 | -3.3 |
| FII | 15.52 | 16.48 | 16.94 | 16.85 | 16.67 | 19.48 | 21.61 | 22.62 | +7.1 |
| DII | 20.24 | 18.31 | 22.38 | 22.59 | 21.7 | 19.6 | 19.56 | 19.4 | -0.84 |
| Public | 28.27 | 29.23 | 28.01 | 27.89 | 28.96 | 28.24 | 26.16 | 25.31 | -2.96 |
Mutual fund holdings · Oct 2026
165 schemes hold this stock
129 the month before.
- UTI Innovation Fund6.1% of NAV
- Kotak MNC Fund5.71% of NAV
- SBI Healthcare Opportunities Fund4.95% of NAV
- Kotak Healthcare Fund4.88% of NAV
- ITI Small Cap Fund4.45% of NAV
- Motilal Oswal Focused Fund4.22% of NAV
- Baroda BNP Paribas Innovation Fund3.85% of NAV
- HDFC Pharma and Healthcare Fund3.7% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ACUTAAS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ACUTAAS
What is the ACUTAAS share price?
ACUTAAS (ACUTAAS) last closed at ₹3,984.00, down 0.18% on the day. Its 52-week range is ₹1,602.50 to ₹4,039.10.
What is the market cap of ACUTAAS?
ACUTAAS has a market capitalisation of about ₹32,712 crore. Its price-to-earnings ratio is 74.8.
How are ACUTAAS's latest results?
ACUTAAS reported revenue of ₹437 crore for Sep 2026, up 42.8% from a year earlier. Net profit was ₹125 crore (up 73.6% year on year). Return on equity was 21.5% in Mar 2026. Promoter holding was 32.66% in Sep 2026, down 3.30 points over 8 quarters.
Who owns ACUTAAS?
As of Sep 2026, shareholding was: Promoter 32.66%, FII 22.62%, DII 19.4%, Public 25.31%.
How many mutual funds hold ACUTAAS?
165 mutual fund schemes held ACUTAAS in October 2026. That compares with 129 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 18 Sep 2025 · Final Dividend - Rs. 1.5
- 25 Apr 2025 · Stock Split From Rs.10/- to Rs.5/-
- 13 Sep 2024 · Final Dividend - Rs. 3
- 18 Sep 2023 · Final Dividend - Rs. 3
- 29 Jul 2022 · Final Dividend - Rs. 3
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.